Aastrom Biosciences (ASTM) Q1/12 Results and Highlights
Net loss of $9.7M, or $0.25 per share Read more…
Net loss of $9.7M, or $0.25 per share Read more…
Net loss was $9.3M, or $0.16 per share Read more…
Net loss of $2.45M or $0.05 per share Read more…
Net loss was $103.9M or $0.70 per share Read more…
Net income was $5M or $0.15 per share Read more…
Geron made the decision to focus exclusively on its oncology programs, Read more…
Maintaining a BUY ranking as the stock appreciates each day – slowly – as market dynamics sputter, but

Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.
I started this blog to add commentary, update news flow and insightful opinions that are intelligent, fit to print and SEC compliant.